Wire Stories
Avistone Announces Preclinical Results for ANS014004, a Type II c-Met Tyrosine Kinase Inhibitor (TKI) at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
BEIJING, China–(BUSINESS WIRE)–Avistone Biotechnology Co., Ltd (“Avistone” or “the Company”), a clinical-stage biotechnology company focused on precision oncology therapeutics, today announced results...